TL;DR
Get everyday helpers delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
MedPage Today published a roundup of comments from clinicians and researchers on developments spanning medical research, testing, fertility care and health policy. The quotes include both reported study findings and concerns voiced by individuals; the source does not provide full study details or independent verification of each claim.
MedPage Today published a weekly quote roundup on Nov. 1, bringing together comments from clinicians and researchers on developments in diabetes research, clinical trials, medical testing and health policy. The remarks highlight questions ranging from the American Diabetes Association’s response to five scientists’ removal from its annual meeting to findings from trials and concerns about software problems affecting an internal medicine board exam.
The roundup quotes Aaron Kelly, a University of Minnesota researcher, criticizing the American Diabetes Association’s final report concerning five scientists who were ousted from this year’s annual meeting. “They’re looking for scapegoats,” Kelly said. The short item does not detail the report’s conclusions, the circumstances of the scientists’ removal or the association’s response to Kelly’s criticism.
Other comments refer to research findings. Hugh Gallagher of Epsom and St Helier University Hospitals said a trial found that low-dose aspirin did not reduce major vascular events among adults with chronic kidney disease. He remarked that, “So 130 years later, we’re still trying to work out what to do with it.” The roundup also reports positive phase III trial results for an investigational osteosarcoma drug tested in adolescents and adults. Nathalie Gaspar of Gustave Roussy described the results as “Something we have not seen for years.”
Several remarks concern clinical practice and health systems. Aaron Gans said he received an “indeterminate” score on his internal medicine board exam after widespread software glitches, raising concern that a systemic data-collection error may have occurred. The roundup also cites an AI-powered tool intended to identify extremely rare sperm in men with azoospermia, potential interactions between GLP-1 drugs and lithium, increases in hemoglobin and hematocrit associated with SGLT2 inhibitors, and obstacles to reforming the No Surprises Act.
Questions Across Research and Care
Taken together, the comments point to issues with consequences beyond individual studies: how professional organizations account for decisions, whether trial results change treatment expectations, and whether testing systems produce reliable outcomes. The exam software account, if substantiated, could affect confidence in how scores are calculated. The roundup does not establish the scale or effects of the reported glitches.
The research remarks also concern decisions that may matter to patients and clinicians, including treatment for chronic kidney disease and osteosarcoma, fertility testing, and possible medication interactions. But these are brief summaries, not clinical guidance. Without study designs, effect sizes or full results, readers cannot judge the findings’ strength or apply them to personal care. The policy comment on the No Surprises Act points to ongoing implementation friction, though the item does not specify the proposed reforms or their likely impact.
Popular right now
Bose QuietComfort True Wireless Noise-Cancelling Earbuds, Black
Dyson V8 Cyclone Cordless Vacuum
Ninja Foodi Smart 6-in-1 Indoor Grill and Air Fryer, 4 Qt, FG551
As an affiliate, we earn on qualifying purchases.
Eight Developments Behind the Quotes
The source is a weekly collection of quotable remarks, rather than a single investigation or announcement. Its eight entries cover separate events and topics, and should not be read as one coordinated development. The roundup was published by MedPage Today on Nov. 1, 2026, and gives speakers’ names and affiliations for the comments.
The underlying developments include a final report from the American Diabetes Association about five scientists removed from its annual meeting; a trial of low-dose aspirin in adults with chronic kidney disease; phase III testing of an investigational osteosarcoma drug; and exam software glitches. The remaining comments address a fertility tool, No Surprises Act reform, possible GLP-1 and lithium interactions, and SGLT2 inhibitors’ association with blood measures. The source supplies no linked study reports or detailed timelines for these items.
““They’re looking for scapegoats.””
— Aaron Kelly, PhD, University of Minnesota
Details Behind the Remarks
The roundup does not provide the full reports, study publications or responses needed to independently evaluate most of the statements. It does not explain the diabetes association’s reasoning, identify the specific osteosarcoma drug, give trial sizes or effect estimates, or describe the methods and limitations of the aspirin study.
It is also unclear how many exam candidates were affected by the software glitches, whether a systemic data error occurred, and whether scores will be reviewed. For the fertility tool, drug-interaction concern and SGLT2 findings, the source gives no performance data, clinical recommendations or details about the evidence. It does not identify the specific changes being considered for the No Surprises Act.
Awaiting Full Reports and Follow-Up
The next useful developments would be publication or release of the underlying reports and research, along with responses from organizations involved. Further information from the American Diabetes Association could clarify the conclusions behind the report and address Kelly’s criticism. Details from the relevant trial investigators would help readers assess the aspirin and osteosarcoma findings.
For the exam issue, a statement from the testing body about the software failures, score handling and any review process would clarify what candidates can expect. The roundup does not give dates for these updates or say that any are scheduled. Until more information is available, the quotes are best understood as attributed reactions and brief descriptions of separate developments, not a complete account of their evidence or outcomes.
Key Questions
What did MedPage Today publish?
It published a weekly roundup of health care quotes on Nov. 1, 2026, covering research, clinical testing and policy topics.
What was Kelly criticizing?
Aaron Kelly criticized the American Diabetes Association’s final report about five scientists ousted from its annual meeting. The roundup does not include the report’s details or the association’s response.
What did the aspirin trial find?
According to the roundup, low-dose aspirin did not reduce major vascular events in a trial involving adults with chronic kidney disease. It does not provide the trial’s size, methods or effect estimates.
Has a systemic error in board exam scoring been confirmed?
No. Aaron Gans said software glitches preceded his “indeterminate” score and raised concern about a possible data-collection error. The roundup does not confirm the cause or say whether scores are being reviewed.
Source: medpagetoday.com
